373 related articles for article (PubMed ID: 35217796)
1. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
[TBL] [Abstract][Full Text] [Related]
2. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
[TBL] [Abstract][Full Text] [Related]
3. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.
Straumann I; Ley L; Holze F; Becker AM; Klaiber A; Wey K; Duthaler U; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2023 Dec; 48(13):1840-1848. PubMed ID: 37258715
[TBL] [Abstract][Full Text] [Related]
6. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.
Becker AM; Klaiber A; Holze F; Istampoulouoglou I; Duthaler U; Varghese N; Eckert A; Liechti ME
Int J Neuropsychopharmacol; 2023 Feb; 26(2):97-106. PubMed ID: 36342343
[TBL] [Abstract][Full Text] [Related]
7. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
Holze F; Vizeli P; Müller F; Ley L; Duerig R; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2020 Feb; 45(3):462-471. PubMed ID: 31733631
[TBL] [Abstract][Full Text] [Related]
8. Safety pharmacology of acute LSD administration in healthy subjects.
Holze F; Caluori TV; Vizeli P; Liechti ME
Psychopharmacology (Berl); 2022 Jun; 239(6):1893-1905. PubMed ID: 34515824
[TBL] [Abstract][Full Text] [Related]
9. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
[TBL] [Abstract][Full Text] [Related]
11. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.
Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H
Psychopharmacology (Berl); 2022 Jun; 239(6):1735-1747. PubMed ID: 34613430
[TBL] [Abstract][Full Text] [Related]
12. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
[TBL] [Abstract][Full Text] [Related]
13. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
14. Greater subjective effects of a low dose of LSD in participants with depressed mood.
Molla H; Lee R; Tare I; de Wit H
Neuropsychopharmacology; 2024 Apr; 49(5):774-781. PubMed ID: 38042914
[TBL] [Abstract][Full Text] [Related]
15. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
Liechti ME; Dolder PC; Schmid Y
Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
[TBL] [Abstract][Full Text] [Related]
16. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
[TBL] [Abstract][Full Text] [Related]
17. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.
Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S
Psychopharmacology (Berl); 2022 Jun; 239(6):1933-1943. PubMed ID: 35076721
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
Family N; Hendricks PS; Williams LT; Luke D; Krediet E; Maillet EL; Raz S
J Psychopharmacol; 2022 Mar; 36(3):321-336. PubMed ID: 35253516
[TBL] [Abstract][Full Text] [Related]
19. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
[TBL] [Abstract][Full Text] [Related]
20. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
